ID21358A - Konjugat yang berguna dalam pengobatan kanker prostat - Google Patents

Konjugat yang berguna dalam pengobatan kanker prostat

Info

Publication number
ID21358A
ID21358A IDW990259A ID990259A ID21358A ID 21358 A ID21358 A ID 21358A ID W990259 A IDW990259 A ID W990259A ID 990259 A ID990259 A ID 990259A ID 21358 A ID21358 A ID 21358A
Authority
ID
Indonesia
Prior art keywords
treatment
prostate cancer
consequent use
consequent
prostate
Prior art date
Application number
IDW990259A
Other languages
English (en)
Indonesian (id)
Inventor
Victor M Garsky
Dong-Mei Feng
Deborah Defeo-Jones
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0A external-priority patent/GB9626309D0/en
Priority claimed from GBGB9718160.6A external-priority patent/GB9718160D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ID21358A publication Critical patent/ID21358A/id

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
IDW990259A 1996-10-30 1997-10-27 Konjugat yang berguna dalam pengobatan kanker prostat ID21358A (id)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2922496P 1996-10-30 1996-10-30
GBGB9626309.0A GB9626309D0 (en) 1996-12-18 1996-12-18 Conjugates useful in the treatment of prostate cancer
US4292197P 1997-04-04 1997-04-04
GBGB9718160.6A GB9718160D0 (en) 1997-08-28 1997-08-28 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
ID21358A true ID21358A (id) 1999-05-27

Family

ID=27451580

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW990259A ID21358A (id) 1996-10-30 1997-10-27 Konjugat yang berguna dalam pengobatan kanker prostat

Country Status (31)

Country Link
EP (1) EP0942754B1 (es)
JP (1) JP2000509407A (es)
KR (1) KR100508199B1 (es)
AR (1) AR008907A1 (es)
AT (1) ATE239509T1 (es)
AU (1) AU726434B2 (es)
BG (1) BG64768B1 (es)
BR (1) BR9712589A (es)
CA (1) CA2268738A1 (es)
CO (1) CO4930281A1 (es)
CZ (1) CZ155599A3 (es)
DE (1) DE69721810T2 (es)
DK (1) DK0942754T3 (es)
DZ (1) DZ2333A1 (es)
EA (1) EA002066B1 (es)
EE (1) EE03858B1 (es)
ES (1) ES2196374T3 (es)
HR (1) HRP970566A2 (es)
HU (1) HUP0000651A3 (es)
ID (1) ID21358A (es)
IL (1) IL129356A0 (es)
IS (1) IS5025A (es)
NO (1) NO992069L (es)
PE (1) PE17399A1 (es)
PL (1) PL333004A1 (es)
PT (1) PT942754E (es)
SK (1) SK57399A3 (es)
TR (1) TR199901485T2 (es)
TW (1) TW425286B (es)
WO (1) WO1998018493A2 (es)
YU (1) YU21399A (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1036093A1 (en) * 1997-12-02 2000-09-20 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
WO2000003737A2 (en) * 1998-07-17 2000-01-27 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble drugs and methods for their production
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP2003518000A (ja) * 1998-12-11 2003-06-03 コールター ファーマシューティカル,インコーポレイティド プロドラッグ化合物およびその調製方法
CA2388700A1 (en) * 1999-10-19 2001-04-26 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
EP1228089A2 (en) * 1999-10-27 2002-08-07 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
KR20030009388A (ko) * 2000-03-15 2003-01-29 브리스톨-마이어스 스퀴브 파마 컴파니 펩티다제-절단성인 표적화 항종양 약물 및 그의 치료상 용도
IL163666A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2005035003A2 (en) * 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
CN100372862C (zh) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
WO2008067495A2 (en) * 2006-11-29 2008-06-05 Rutgers, The State University Of New Jersey Chemotherapeutic conjugates and methods of use
CN101225094A (zh) * 2007-01-18 2008-07-23 天津和美生物技术有限公司 具有抗癌活性的蒽醌四环类化合物
BRPI1009521A2 (pt) * 2009-03-09 2016-03-15 Ktb Tumorforschungs Gmbh pró-drogas.
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
JP2015508414A (ja) 2012-01-12 2015-03-19 イエール ユニバーシティ E3ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
EP3903818A1 (en) 2015-11-19 2021-11-03 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN116635054A (zh) 2020-12-22 2023-08-22 科比欧尔斯公司 包括四肽部分的化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
AU708475B2 (en) * 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia

Also Published As

Publication number Publication date
EP0942754B1 (en) 2003-05-07
ES2196374T3 (es) 2003-12-16
EA002066B1 (ru) 2001-12-24
JP2000509407A (ja) 2000-07-25
KR100508199B1 (ko) 2005-08-17
HRP970566A2 (en) 1998-08-31
DE69721810D1 (de) 2003-06-12
BR9712589A (pt) 1999-10-26
WO1998018493A3 (en) 1998-07-23
PT942754E (pt) 2003-08-29
IS5025A (is) 1999-04-13
NO992069D0 (no) 1999-04-29
DK0942754T3 (da) 2003-08-04
BG103436A (en) 2000-04-28
AU726434B2 (en) 2000-11-09
YU21399A (sh) 2000-03-21
ATE239509T1 (de) 2003-05-15
CO4930281A1 (es) 2000-06-27
AR008907A1 (es) 2000-02-23
KR20000052970A (ko) 2000-08-25
AU5149798A (en) 1998-05-22
EP0942754A2 (en) 1999-09-22
NO992069L (no) 1999-06-30
PL333004A1 (en) 1999-11-08
EA199900428A1 (ru) 2000-02-28
CA2268738A1 (en) 1998-05-07
SK57399A3 (en) 2000-01-18
BG64768B1 (bg) 2006-03-31
DE69721810T2 (de) 2004-03-11
EE03858B1 (et) 2002-10-15
HUP0000651A2 (hu) 2000-06-28
HK1024876A1 (en) 2000-10-27
TW425286B (en) 2001-03-11
PE17399A1 (es) 1999-02-20
EE9900179A (et) 1999-12-15
WO1998018493A2 (en) 1998-05-07
DZ2333A1 (fr) 2002-12-28
HUP0000651A3 (en) 2001-12-28
CZ155599A3 (cs) 1999-10-13
TR199901485T2 (xx) 1999-08-23
IL129356A0 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
ID17156A (id) Zat-zat anti koagulan yang berguna dalam pengobatan trombosis
HUS1500001I1 (hu) ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
GB2335153B (en) Treatment of water
GB9903841D0 (en) Diagnosis and treatment of cancer
HUP0000651A3 (en) Conjugates useful in the treatment of prostate cancer
FI955709L (fi) Indolokarbatsolijohdannaisten käyttö eturauhasen patologisten tilojen hoidossa
HUP0004326A3 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
ID24735A (id) Konjugat-konjugat yang berguna pada pengobatan kanker prostat
IL147748A0 (en) Use of etodolac to treat cancer
GB9912159D0 (en) Improvements in and relating to the treatment of water
GB9811598D0 (en) Diagnosis and treatment of cancer
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
GB9819999D0 (en) Treatment of cancer
GB2343629B (en) Treatment of cellulite
GB9606293D0 (en) Treatment of cancers and other tumours
ID19871A (id) Turunan-turunan kuinoksalin yang berguna dalam terapi
AUPO851597A0 (en) Treatment of prostate cancer
GB9617941D0 (en) New approach to the treatment of prostate cancer
GB9822401D0 (en) Device for use in treatment of hair
GB9626309D0 (en) Conjugates useful in the treatment of prostate cancer
GB9624170D0 (en) Conjugates useful in the treatment of prostate cancer
SI0942754T1 (en) Conjugates useful in the treatment of prostate cancer
SI1011649T1 (en) Use of endipalene in the treatment of psoriasis